0000000000309975

AUTHOR

Nicholas P. Van Der Meulen

0000-0001-6077-5594

showing 3 related works from this author

From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies

2019

Precision oncology is being driven by rapid advances in novel diagnostics and therapeutic interventions, with treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from other patients with similar clinical presentations. Inherent in the theranostics paradigm is the assumption that diagnostic test results can precisely determine whether an individual is likely to benefit from a specific treatment. As part and integral in the current era of precision oncology, theranostics in the context of nuclear medicine aims to identify the appropriate molecular targets in neoplasms (diagnost…

Treatment responseNeurotensin receptor 1Somatostatin receptorbusiness.industryContext (language use)First in humanBioinformaticsBench to bedside030218 nuclear medicine & medical imagingBiomarker (cell)Translational Research Biomedical03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisRadionuclide therapyAnimalsHumansMedicineRadiology Nuclear Medicine and imagingNuclear MedicineRadiopharmaceuticalsPeptidesbusinessSeminars in Nuclear Medicine
researchProduct

CERN-MEDICIS: A Review Since Commissioning in 2017

2021

The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and development in nuclear medicine using non-conventional radionuclides. Since then, fourteen institutes, including CERN, have joined the collaboration to drive the scientific program of this unique installation and evaluate the needs of the community to improve the research in imaging, diagnostics, radiation therapy and personalized medicine. The facility has been built as an extension of the ISOLDE (Isotope Separator On Line DEvice) facility at CERN. Handling of open radioisotope sources is made possible thanks to i…

Medicine (General)HIGH-ENERGYIon beamNuclear engineeringHigh resolutionProton Synchrotron Booster01 natural sciencesmedicalISOLDE030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciencesR5-9200302 clinical medicineMedicine General & InternallawGeneral & Internal Medicine0103 physical sciencesCERNNuclear Physics - ExperimentBeam dump010306 general physicsradionuclidesOriginal ResearchLarge Hadron ColliderScience & TechnologyGeneral MedicineMass separationHandling systemmass separationBeamlineMEDICISMedicineEnvironmental scienceLife Sciences & Biomedicine
researchProduct

Production of mass-separated Erbium-169 towards the first preclinical in vitro investigations

2021

The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclid…

Medicine (General)Health Physics and Radiation Effectselectromagnetic isotope separationEr-169030218 nuclear medicine & medical imagingIsotope separationlaw.invention03 medical and health sciencesR5-9200302 clinical medicineErbium-169lawLASER RESONANCE IONIZATIONIonizationEr-169; activity standardization; electromagnetic isotope separation; in vitro studies; lanthanide-separation; laser resonance ionizationNeutron irradiationOriginal Researchin vitro studiesRadionuclideChemistryRadiochemistryGeneral MedicineLANTHANIDE-SEPARATIONIn vitroELECTROMAGNETIC ISOTOPE SEPARATIONER-169030220 oncology & carcinogenesisRadionuclide therapyMedicinelanthanide-separationactivity standardizationSpecific activitylaser resonance ionizationACTIVITY STANDARDIZATIONIN VITRO STUDIESFrontiers in Medicine
researchProduct